OncoMatch/Clinical Trials/NCT06383780

Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.

Is NCT06383780 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including GP combined with Tislelizumab and TPC combined with Tislelizumab for nasopharyngeal carcinoma.

Phase 3RecruitingXIANG YANQUNNCT06383780Data as of May 2026

Treatment: GP combined with Tislelizumab · TPC combined with Tislelizumab — This is a prospective, open-label phase III clinical trial evaluating the efficacy and safety of the GP（Gemcitabine combined with cisplatin） regimen in combination with Tislelizumab versus the TPC（cisplatin, nab-paclitaxel and capecitabine）regimen in combination with Tislelizumab for the first-line treatment of Nasopharyngeal Carcinoma patients With Bone Metastasis.

Check if I qualify

Extracted eligibility criteria

Cancer type

Head and Neck Squamous Cell Carcinoma

Disease stage

Required: Stage IVB

Metastatic disease required

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Blood counts

Hemoglobin > 8.0 g/dl; ANC > 1,500/mm3; Platelet count > 100,000/μl

Liver function

Total bilirubin ≤ 1.5x ULN; ALT and AST < 2.5x ULN (or < 5x ULN with liver metastases); alkaline phosphatase < 4x ULN; PT INR/PTT < 1.5x ULN

Good organ function:Hemoglobin > 8.0 g/dl; Absolute neutrophil count (ANC) >1,500/mm3; Platelet count> 100,000/μl; Total bilirubin ≤ 1.5 times the upper limit of normal (ULN); Alanine aminotransferase and glutamate aminotransferase < 2.5 ULN (upper limit of normal), (alanine aminotransferase and aspartate aminotransferase < 5 ULN in patients with liver metastases), alkaline phosphatase< 4 ULN;Prothrombin time (PT) international normalized ratio/prothrombin time (PTT) < 1.5 ULN, serum muscle；Anhydride< 1.5ULN.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify